Choice of Direct Oral Anticoagulants for Atrial Fibrillation

General Recommendations for Anticoagulation in AF

• The European Society of Cardiology recommends that DOACs (apixaban, dabigatran, edoxaban, and rivaroxaban) are preferred over vitamin K antagonists (VKAs) like warfarin for stroke prevention in non-valvular atrial fibrillation 1
• The European Society of Cardiology recommends oral anticoagulation for all eligible patients with AF who have stroke risk factors (CHA₂DS₂-VA score ≥2), and should be considered for those with a score of 1 1
• The European Society of Cardiology recommends that full standard doses of DOACs should be used unless specific dose-reduction criteria are met 1

Special Populations

Patients Requiring PCI

• The American Heart Association recommends that for AF patients undergoing percutaneous coronary intervention (PCI), a DOAC is preferred over a VKA when combined with antiplatelet therapy 2
• The American Heart Association recommends that in this setting, the choice of DOAC should be based on the patient's bleeding and thrombotic risk profiles 2

Specific Contraindications for DOACs

• The European Society of Cardiology recommends that DOACs are contraindicated in patients with mechanical heart valves, and patients with moderate to severe mitral stenosis should receive warfarin rather than DOACs 3

Clinical Decision Algorithm

• The European Society of Cardiology recommends assessing stroke risk using CHA₂DS₂-VA score, and if anticoagulation is indicated (score ≥1), choose a DOAC over warfarin unless contraindicated 1

Common Pitfalls and Caveats

• The European Society of Cardiology recommends avoiding failure to use full standard doses of DOACs unless specific dose-reduction criteria are met 1
• The American College of Chest Physicians recommends avoiding inappropriate switching between anticoagulants without considering the specific pharmacokinetic profiles of each agent 4
• The European Society of Cardiology recommends avoiding using DOACs in patients with mechanical heart valves where they are contraindicated 3
• The European Society of Cardiology recommends reassessing stroke and bleeding risk at periodic intervals to guide anticoagulation decisions 1
• The European Society of Cardiology recommends avoiding combining anticoagulants with antiplatelet agents unnecessarily, which significantly increases bleeding risk 1